This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Deutschinoff, A. Articles by Grozdinsky, L. Search for Related Content PubMed PubMed Citation Articles by Deutschinoff, A. Articles by Grozdinsky, L. Social Bookmarking                         What's this?

Rheological and Anticoagulant Therapy of Patients with Chronic Peripheral Occlusive Arterial Disease (COAD)

Section of Angiology & Haemostaseology, National Center of Cardiovascular Diseases, Sofia, Bulgaria

L. Grozdinsky

Section of Angiology & Haemostaseology, National Center of Cardiovascular Diseases, Sofia, Bulgaria

In the course of a six-month study, a three-subgroup cohort of 113 patients (103 m, 10 f, mean age 58±8 years) with angiographically proven occlusive peripheral arterial disease (COAD) Fontaine stage II was analyzed regarding the therapeutic (improvement of walking performance) and prophylactic (prevention of new vascular events) effects of oral treatment with three different drug regimens. Group A (38 patients) was treated with the anticoagulants phenprocoumon or acenocoumarol; group B (32 patients), with the same anticoagulants plus pentoxifylline—800—1200 mg per day; and group C (43 patients) received irregular treatment with various vasodilators, such as xanthinolnicotinate, naftidrofuryl, pyridylmethanol, and others. At the end of the trial period a significant increase in systolic ankle pressure index and walking distance was observed in group B whereas the two other groups showed minor changes only. The elevated plasma fibrinogen concentration in group B was also significantly decreased. The percentage of atherosclerotic complications such as new arterial thrombosis in the lower limbs, newly appeared stenocardia, myocardial infarction, transient ischemic attack (TIA), and stroke was highest in group C (20%), relatively lower in group A (10%), and lowest in group B (3%). The percentage of hemorrhagic complications was minimal, with no significant differences between group A and group B. These complications were mild and disappeared quickly. The combined therapy with anticoagulants and pentoxifylline had a marked therapeutic and probably prophylactic effect as regards thromboembolic complications in patients with COAD and other localizations of atherosclerosis.

Angiology, Vol. 38, No. 5, 351-358 (1987)
DOI: 10.1177/000331978703800501


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. G. Dettori, M. Pini, A. Moratti, M. Paolicelli, P. Basevi, R. Quintavalla, C. Manotti, and C. Di Lecce Acenocoumarol and Pentoxifylline in Intermittent Claudication. A Controlled Clinical Study Angiology, April 1, 1989; 40(4): 237 - 248. [Abstract] [PDF]

				R. Muller and P. Musikic Hemorheology in Surgery A Review Angiology, August 1, 1987; 38(8): 581 - 592. [Abstract] [PDF]

				A. Radmilovic, Z. Boric, T. Naumovic, M. Stamenkovic, and P. Musikic Shunt Thrombosis Prevention in Hemodialysis Patients A Double-Blind, Randomized Study: Pentoxifylline vs Placebo Angiology, July 1, 1987; 38(7): 499 - 506. [Abstract] [PDF]